[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin,2021,71(3):209-249. [2] Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl),2022,135(5):584-590. [3] 莫春明,黄德佳,韦惠章,等.TACE术治疗的原发性PLC患者血清IL-33水平变化及其对发热的鉴别意义探讨.实用肝脏病杂志,2023,26(6):887-890. [4] Hu YD, Zhang H, Tan W, et al. Impact of hepatectomy and postoperative adjuvant transarterial chemoembolization on serum tumor markers and prognosis in intermediate-stage hepatocellular carcinoma. World J Gastrointest Surg,2023,15(12):2820-2830. [5] Zhao GS, Song YX, Sun JB, et al. Efficacy and safety of calliSpheres© microspheres drug-eluting beads transarterial chemoembolization in GCLM combined trans-arterial infusion therapy for treating primary focus of gastric cancer: a multi-center retrospective study. Expert Rev Anticancer Ther,2023,23(9):1009-1016. [6] Qin S, Bi F, Gu S,et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial. J Clin Oncol,2021,39(27):3002-3011. [7] Zhu D, Ma K, Yang W, et al. Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study. Front Oncol,2022,12:1057560. [8] Liu W, Xie Z, Shen K, et al. Analysis of the safety and effectiveness of TACE combined with targeted immunotherapy in the treatment of intermediate and advanced hepatocellular carcinoma. Med Oncol,2023,40(9):251. [9] 中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南(2024年版).中华肝脏病杂志,2024,32(7):581-630. [10] 中华预防医学会肝胆胰疾病预防与控制专业委员会,中国研究型医院学会肝病专业委员会,中华医学会肝病学分会,等.原发性肝癌的分层筛查与监测指南(2020年版).临床肝胆病杂志,2021,37(2):286-295. [11] 中国医师协会介入医师分会临床诊疗指南专委会.中国肝细胞癌经动脉化疗栓塞(TACE)治疗临床实践指南(2023年版).中华医学杂志,2023,103(34):2674-2694. [12] Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol,2020,72(2):288-306. [13] Zhou T, Zhang Y, Lu Y, et al. The efficacy of combined use of Huai’er Granules in the treatment of primary liver cancer: an updated systematic review and meta-analysis. Pharmaceuticals (Basel),2025,18(6):884. [14] 唐亮,陈曦,王文高,等.TACE联合直线加速器三维适形放疗治疗中晚期原发性肝癌患者近期临床疗效研究.实用肝脏病杂志,2023,26(3):416-419. [15] Lee SH, Lee HT, Lim H, et al. Crystal structure of PD-1in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy. Biochem Biophys Res Commun,2020,527(1):226-231. [16] Yuan Y, He W, Yang Z, et al. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Int J Surg,2023,109(5):1222-1230. [17] Hu Z, Yang A, Su G, et al. Huai’er restrains proliferative and invasive potential of human hepatoma SKHEP-1 cells partially through decreased Lamin B1 and elevated NOV. Sci Rep,2016,6:31298. [18] 彭贺,郝建玲,黄建业,等.TACE术联合靶向和免疫治疗原发性肝癌患者疗效研究.实用肝脏病杂志,2025,28(4):593-596. [19] Luo S, Hu H. Huaier granule prolongs overall survival after curative resection of hepatocarcinoma carcinoma: a propensity score analysis. J Ethnopharmacol,2023,301:115774. [20] 李榕,李文利,袁国盛,等.肝动脉灌注化疗术联合靶免对比经动脉插管化疗栓塞术联合靶免治疗中不可切除的原发性肝癌患者术后引起肝损伤的研究.中华肝脏病杂志,2023,31(11):1163-1168. |